当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Therapeutically Growth in Oligodendroglia Fate Induction via Trans Differentiation of Stem Cells for Neurodegenerative Therapy

Darcy Armour

The benefits of stem cell therapy and research are undeniable given how frequently they are used to treat demyelinating illnesses and neurodegenerative diseases. Prior to transplantation or disease modelling research, stem cells are induced into several cell lineages, both adult and progenitor - belonging to each germ layer - in cell replacement treatment. The nervous system contains a large number of glial cells, including oligodendrocytes, which can remyelinate axons that have lost or damaged myelin sheaths as well as myelinate newly formed neurons. Yet, myelin breakdown and regeneration are drastically outpaced by demyelinating illnesses. Mesenchymal stem cells (MSCs) have been stimulated to transdifferentiate in order to make up for this loss, examine the abnormalities in remyelination pathways, and accelerate full recovery in such individuals.